RxDoctor Payments Data

Paul Dash, MD

Neurology · Baltimore, MDNPI 1942237987

Payments from drug & device makers

$21,180in general payments, 2019–2025

Across 334 payments — averaging $63.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$13K
  • AbbVie$1K
  • Lilly USA, LLC$1K
  • Teva Pharmaceuticals USA, Inc.$1K
  • Amgen$942
  • Lundbeck LLC$568
  • plus $3K from 27 others

What the payments were for

  • Consulting fees$9304%
  • Speaking & faculty fees$11,62555%
  • Food & beverage$8,25239%
  • Education$3722%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,180 in reported general payments places this provider in the 75th percentile of 442 neurology providers in Maryland.

See all neurology providers in Maryland

Medicare billing

Part B allowed, 2024
$25,320
Medicare patients
165
Services billed
215

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Emgality PenGalcanezumab-Gnlm88$86,727
Nurtec OdtRimegepant Sulfate41$52,595
Aimovig AutoinjectorErenumab-Aooe30$48,099
Ajovy AutoinjectorFremanezumab-Vfrm28$35,931
QuliptaAtogepant26$27,555
ZavzpretZavegepant Hcl11$11,855
Gabapentin96$2,638
Sumatriptan Succinate68$2,517
Entacapone17$2,285
RizatriptanRizatriptan Benzoate120$1,506
Levetiracetam37$1,291
Pregabalin19$1,031
Divalproex Sodium20$937
Donepezil Hcl68$841
Topiramate36$698

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt, Zavzpret$242$64,45052 claims
AbbVieQulipta$1,429$27,55526 claims
Upsher-smith Laboratories LLCTopiramate$22$69836 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 442 neurology providers in Maryland.

Other neurology in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →